PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16767754

Aflatoxin M1 effects on Xenopus laevis development.

Claudio Vismara·Andrea Di Muzio·Silvia Tarca·Marta Lucchino·Ingrid Foti·Francesca Caloni
View original source ↗Export metadata ↓

Abstract

BACKGROUND: The principal Aflatoxin B(1) (AFB(1)) hydroxylated metabolite excreted in milk is Aflatoxin M(1) (AFM(1)) classified in group 2B by the International Agency for Research on Cancer (IARC). Human exposure to AFM(1) is due to the consumption of contaminated dairy products and partly to endogenous production through AFB(1) liver metabolism. METHODS: Since no data are available on AFM(1) embryotoxicity, its lethal and teratogenic potential was investigated using the Frog Embryo Teratogenesis Assay-Xenopus (FETAX). Stage-8 blastulae were exposed to AFM(1) at 1, 4, 16, 64, and 256 microg/L concentrations until stage 47, free-swimming larva. RESULTS: A slight increase of mortality and malformed larva percents was found in AFM(1)-exposed groups but these differences were not statistically significant in comparison with the controls. CONCLUSIONS: Therefore, AFM(1) is a non-embryotoxic compound when evaluated with a FETAX model at concentrations under the conditions tested. However, AFM(1) merits further studies using mammals as experimental models to identify a possible risk during human pregnancy.

Explore related subjects

Aflatoxin M1AnimalsEmbryo, NonmammalianLarvaXenopus laevisJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Claudio Vismara, Andrea Di Muzio, Silvia Tarca, Marta Lucchino, Ingrid Foti, Francesca Caloni. 2006. Aflatoxin M1 effects on Xenopus laevis development.. https://doi.org/10.1002/bdrb.20079

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Presence of aflatoxin M1 in pasteurized milk from Morocco.

Fifty four samples of pasteurized milk produced by five different dairies from Morocco were surveyed for the presence of aflatoxin M1 (AFM1) using immunoaffinity columns and liquid chromatography coupled to fluorescence detection. Confirmation of AFM1 identity in positive samples was based on the formation of AFM1 hemi-acetal derivative (AFM2a) after derivatization with trifluoracetic acid. Analytical results showed that 88.8% of the samples were contaminated with AFM1; 7.4% being above the maximum level of 0.05 microg/L set by the Moroccan and European regulations for AFM1 in liquid milk. The incidence of AFM1 in milk from these dairies was 100, 92.3, 90, 83.3 and 77.7% respectively, with AFM1 levels ranging from 0.001 to 0.117 microg/L and a mean value of 0.0186 microg/L. Based on the results presented in this study, the estimated daily intake of AFM1 was 3.26 ng/person/day. In this work, data on the natural occurrence of AFM1 in pasteurized milk produced in Morocco is presented for the first time.

Aflatoxin M1↗
PubMed2006

Aflatoxin M1 determination in cheese by liquid chromatography-tandem mass spectrometry.

A new method for determining aflatoxin M1 (AFM1) in cheese by liquid chromatography-tandem mass spectrometry has been developed. Two methodologies were compared for sample extraction. The first one involves sample extraction with dichloromethane for hard, aged cheese or acetone for fresh cheese and includes a preliminary matrix solid-phase dispersion-extraction step before solid-phase extraction (SPE) clean-up by a Carbograph-4 cartridge. The second method uses a water/methanol solution (90:10, v/v) extraction at 150 degrees C before clean-up. The average recoveries of AFM1 from samples spiked at levels of 0.25-0.45 microg/kg, were 81-92% and the precision (RSD) ranged from 3 to 7% with the first method, whilst the average recoveries were 79-84%, and RSD ranged from 7 to 15% for the second method. Due to different matrix effect, the quantification limits were 0.019-0.025 microg/kg in the first case and 0.048-0.143 microg/kg in the second one, depending on cheese typology.

Aflatoxin M1↗
PubMed2006

Sample size and statistical power assessing the effect of interventions in the context of mixture distributions with detection limits.

Often in randomized clinical trials and observational cohort studies, a non-negative continuously distributed response variable is measured in treatment and control groups. In the presence of true zeros for the response variable, a two-part zero-inflated log-normal model (which assumes that the data has a probability mass at zero and a continuous response for values greater than zero) is usually recommended. However, in some environmental health and human immunodeficiency virus (HIV) studies, quantitative assays for metabolites of toxicants, or quantitative HIV RNA measurements are subject to left-censoring due to values falling below the limit of detection (LD). Here, a zero-inflated log-normal mixture model is often suggested since true zeros are indistinguishable from left-censored values due to the LD. When the probabilities of true zeros in the two groups are not restricted to be equal, the information contributed by values falling below LD is used only to estimate the probability of true zeros in the context of mixture distributions. We derived the required sample size to assess the effect of a treatment in the context of mixture models with equal and unequal variances based on the left-truncated log-normal distribution. Methods for calculation of statistical power are also presented. We calculate the required sample size and power for a recent study estimating the effect of oltipraz on reducing urinary levels of the hydroxylated metabolite aflatoxin M(1) (AFM(1)) in a randomized, placebo-controlled, double-blind phase IIa chemoprevention trial in Qidong, China. A Monte Carlo simulation study is conducted to investigate the performance of the proposed methods.

Aflatoxin M1↗